Intratio
Quantitative Research
Skip to main content
AI Market Summary
Loading market intelligence...
  • Sign in
    My account
    Logout
AI 90-DAY FORECAST
BULLISH SIGNAL DETECTED · Alpha
██.█% Sign up free to reveal

Immunovant, Inc. (IMVT) AI Forecast

Our AI ranks Immunovant, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.

✓ Free account • ✓ 30-day free trial

$IMVT Bullish Signal Full forecast available
Sign Up Free

Immunovant, Inc. (IMVT) Stock Forecast Sept. 21, 2026

Immunovant, Inc. (IMVT) AI Stock Price Forecast & Investment Analysis

Immunovant, Inc. Stock Price Chart and Technical Analysis

Loading chart...

Immunovant, Inc. (IMVT) - Comprehensive Stock Analysis & Investment Research

Deep dive into Immunovant, Inc.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Analysis updated on September 21, 2026 (UTC)

Immunovant, Inc. Investment Summary

When evaluating whether Immunovant, Inc. (IMVT) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.

Company Profile

Immunovant, Inc. (IMVT) operates within the Life Sciences sector, specifically in the Biological Products, (No Diagnostic Substances) industry. . With a market capitalization of $8 billion, the company is a mid-cap stock that typically offers a balance between growth potential and established business operations.

Financial Performance Analysis

Our comprehensive financial analysis covers Immunovant, Inc.'s revenue, profitability metrics, balance sheet strength, and cash flow generation...

AI Price Predictions

Get AI-powered 7-day, 30-day and 90-day price forecasts for Immunovant, Inc. along with confidence scores and detailed analysis...

Investment Considerations

Expert analysis of whether Immunovant, Inc. is suitable for your investment objectives, risk tolerance, and time horizon...

Continue Reading Full Analysis

Get the complete investment breakdown for Immunovant, Inc.

Sign Up Free
Corporate Identity

Immunovant, Inc. (Stock Symbol: IMVT) is a prominent company operating within the Life Sciences sector, with a specific focus on the Biological Products, (No Diagnostic Substances) industry. The company's shares are publicly traded on the Nasdaq exchange.

Leadership & Workforce

Detailed information about Immunovant, Inc.'s leadership team, workforce size, and organizational structure...

Market Classification

Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for Immunovant, Inc....

Sector & Industry Analysis

In-depth sector dynamics and industry context for Immunovant, Inc....

Unlock Full Company Profile

Get complete details about Immunovant, Inc.

Sign Up Free
Revenue & Growth Analysis
Profitability Metrics

Net profit margin, gross margin, and operating margin analysis for Immunovant, Inc....

Market Valuation

P/E ratio, price-to-book, and valuation multiples for Immunovant, Inc....

Return Metrics

Return on equity (ROE), return on assets (ROA), and capital efficiency for Immunovant, Inc....

Unlock Financial Analysis

Get complete financial metrics for Immunovant, Inc.

Sign Up Free
AI ANALYSIS AVAILABLE

Unlock Immunovant, Inc.'s AI Price Forecast

Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

4537 Stocks in the out-of-sample test
73.7% Rebalance periods with a positive net return
Daily Updates
Start 30-Day Free Trial →

✓ 30-day free trial • ✓ Cancel anytime

Strategic Market Position

Immunovant, Inc. strategically competes in the highly dynamic Biological Products, (No Diagnostic Substances) marketplace. As a mid-cap company, it occupies an attractive position balancing growth potential with established operations. Mid-caps often represent the 'sweet spot' for investors seeking companies that have proven their business models but still have meaningful runway for expansion. These companies are large enough to have competitive advantages but nimble enough to adapt quickly to market changes.

Industry Competitive Landscape

Immunovant, Inc. competes within the Life Sciences sector, navigating the competitive dynamics and market forces specific to this industry. The company's competitive position depends on its ability to differentiate through product quality, cost efficiency, customer relationships, or other strategic advantages relevant to its specific market segment.

Operational Efficiency
Financial Strength & Leverage

Current ratio of 7.27 demonstrates strong short-term liquidity with current assets significantly exceeding current liabilities. This provides a substantial buffer for meeting near-term obligations and handling unexpected financial needs.

Immunovant, Inc. (IMVT) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Immunovant, Inc. stock analysis.

Deep dive into Immunovant, Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Immunovant, Inc. stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Immunovant, Inc.:

P/B Ratio 10.38x
Market Cap $7.63B
EPS $-2.81
Book Value/Share $3.56
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Immunovant, Inc. converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Immunovant, Inc.: An ROE of -73.2% indicates room for improvement in shareholder value creation.

ROE -73.2%
ROA -63.1%
Tax Rate 0.1%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Immunovant, Inc.'s ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Immunovant, Inc.: A current ratio of 7.27 indicates strong liquidity.

Current Ratio 7.27x
D/E Ratio 0.16x
Financial Leverage 1.16x
Working Capital $734M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Immunovant, Inc.'s ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Immunovant, Inc.:

Operating Cash Flow -$414M
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Immunovant, Inc. uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Immunovant, Inc.:

Understanding Financial Statement Data

What these metrics mean: Key figures from Immunovant, Inc.'s income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Immunovant, Inc.:

Income Statement
Net Income -$538M
R&D Expense $498M
Balance Sheet Highlights (USD millions)
Total Current Assets $851M (99.9% of assets)
Cash & Short-term Investments $798M (93.6% of assets)
Accounts Receivable $700K (0.1% of assets)
Total Liabilities $117M (13.7% of assets)
Short-term Debt $107M (12.5% of assets)
Dividend & Shareholder Information
Shares Outstanding 207M

Latest Immunovant, Inc. Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Immunovant, Inc. (IMVT) stock price and investment outlook.

📰 Loading...

Where IMVT sits on the market map

Explore the map →

Immunovant, Inc. Industry Peers - Biological Products, (No Diagnostic Substances)

Companies classified under the same SEC industry code as Immunovant, Inc. (Biological Products, (No Diagnostic Substances)): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.

Company Ticker Symbol 90-Day AI Forecast (Alpha) Market Cap (USD M) P/E Ratio P/B Ratio
IMVT ██% $7.63B x 10.4x
AMGN ██% $212.55B 24.3x 18.2x
GILD ██% $186.13B x 15.7x
MRNA ██% $61.50B x 9.1x
ARGX ██% $61.15B x x
RVMD ██% $40.93B x 15.7x
BIIB ██% $32.34B 23.6x 1.7x
BNTX ██% $24.78B x x
MESO ██% $19.62B x x
NBIX ██% $14.86B 21.1x 4.0x
EXEL ██% $14.18B x 7.7x
HALO ██% $12.76B 30.9x 88.9x
TECH ██% $11.35B 62.4x 5.4x
TWST ██% $10.47B x 23.5x
APGE ██% $10.22B x x
RGEN ██% $9.98B 240.3x 4.7x
KRYS ██% $9.97B 41.3x 7.3x
KYMR ██% $9.79B x 6.5x
QGEN ██% $9.40B x 2.5x
IBRX ██% $8.99B x x
PCVX ██% $8.65B x 3.1x
CGON ██% $6.94B x 6.7x
SRRK ██% $5.68B x 22.4x
CRSP ██% $5.64B x 3.2x
IOVA ██% $4.64B x 6.3x
ADPT ██% $4.45B x 31.1x
RLAY ██% $4.13B x 4.6x
DBVT ██% $3.58B x 21.2x
TARS ██% $3.43B x 9.9x
DNLI ██% $3.27B x 3.9x
BEAM ██% $2.61B x 2.4x
BCRX ██% $2.24B x x
SCNI ██% $2.16B x 275.4x
ADMA ██% $2.13B 12.6x 5.2x
KOD ██% $2.06B x 33.7x
RXRX ██% $2.05B x 2.2x
VCEL ██% $2.05B 84.6x 5.5x
ALVO ██% $1.83B x x
VIR ██% $1.79B x 1.8x
COAG ██% $1.77B x 3.9x
NVAX ██% $1.67B x x
IMCR ██% $1.65B x 3.9x
TSHA ██% $1.64B x 4.2x
CGEM ██% $1.37B x 4.3x
MGTX ██% $1.27B 16.1x 5.9x
VOR ██% $1.27B x x
MAZE ██% $1.25B x 2.8x
REPL ██% $1.23B x 11.7x
JATT ██% $1.17B x 6.0x
ODTX ██% $1.17B x 2.8x
IMTX ██% $1.16B x x
VALN ██% $1.14B x x
GLUE ██% $1.03B x 2.1x
SLDB ██% $955M x 2.6x
SANA ██% $928M x 6.0x
CADL ██% $858M x 6.8x
FDMT ██% $841M x 2.1x
AURA ██% $660M x 2.1x
ALLO ██% $584M x 1.3x
PRME ██% $566M x 14.2x
Reveal all forecasts See exact % predictions for all competitors
Sign up free

Frequently Asked Questions - Immunovant, Inc. Stock Forecast

How accurate are Immunovant, Inc. stock predictions?

A per-ticker accuracy statistic for IMVT is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

What factors influence Immunovant, Inc. stock price forecasts?

Our analysis considers Immunovant, Inc.'s financial metrics, Life Sciences sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Immunovant, Inc. a good investment in 2026?

Based on our AI analysis, Immunovant, Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Immunovant, Inc. forecasts updated?

Immunovant, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on September 21, 2026.

Want a simpler view of Immunovant, Inc.?

View simplified analysis on AI Stock Finder →

My Portfolio

Investment Dashboard

Loading your portfolio...